The number of active prescriptions for the opioid disorder treatment drug buprenorphine remained constant during the first year of the COVID-19 pandemic, but the number of new prescriptions for the treatment was far below what would normally have been expected, according to a new RAND Corporation study.
from Medical Xpress - latest medical and health news stories https://ift.tt/zmU10Oa
